Back

ANG1005 in Leptomeningeal Disease From Breast Cancer

A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician’s Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)

  • Clinical Trial Information

    Trial Contact: Manchola-Orozco, Carolina; Walton, Sherri

    Trial Phone: 321.841.7293 ; 321.841.1907

  • IRB No: 18.131.09

    Protocol Abbrev: ANG1005-CLN-07

    Principal Investigator: Nicholas G. Avgeropoulos, MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: ANG1005

    Treatment: paclitaxel trevatide, capecitabine, eribulin, high-dose IV methotrexate

    Therapies Involved: Medication

    ClinicalTrials.gov ID: NCT03613181

  • Objective

    Primary Objective: To determine the overall survival (OS) for patients randomized to ANG1005 vs. Physician’s Best Choice

    Secondary Objective: To further evaluate the efficacy of ANG1005 vs. Physician’s Best Choice in terms
    of:
    •  CNS (leptomeningeal and parenchymal) progression-free survival (PFS)
    •  CNS (leptomeningeal and parenchymal) clinical benefit rate (stable disease or better) at 3, 6 and 12 months
    •  6-Month and 12-month overall survival rates
    •  LC response rate (RR) and duration of response
    •  OS for triple negative (HER2-/ER-/PR-) patients

  • Key Eligibility

    1. Histologically or cytologically documented HER2-negative breast cancer
    2. At least 2 months of expected OS.
    3. Newly diagnosed LC, with radiological and/or cytological confirmation.
    4. Documented history of parenchymal BM that has been previously treated with at least one course of radiation therapy.
    5. Neurologically stable, receiving stable doses of corticosteroids, RT and anticonvulsants (no enzyme-induced antiepileptic drugs [EIAEDs]) for >1 week prior to first dose.
    6. Eastern Cooperative Oncology Group (ECOG) performance status grade <2.
    7. Adequate laboratory test results for organ systems prior to first dose